|
시장보고서
상품코드
2076125
신경병성 안구 통증 시장 : 약제 클래스별, 유통 채널별 및 지역별Neuropathic Ocular Pain Market, By Drug Class, By Distribution Channel, And by Region |
||||||
신경병성 안구 통증 시장은 2026년에 2억 1,660만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 2억 7,240만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 3.3%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 2억 1,660만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 3.30% | 2033년 시장 규모 예측 : | 2억 7,240만 달러 |
신경성 통증은 일반적으로 만성적인 통증을 동반하는 질환입니다. 대부분의 경우 만성적이고 진행성인 신경질환에 의해 유발되지만, 외상이나 감염의 결과로 발생하기도 합니다. 안구 신경병증성 통증(각막 신경병증성 통증이라고도 함)은 일반적으로 통증을 유발하지 않는 자극에 대해 각막에 통증이 발생하는 상태입니다. 이는 각막의 신경이 반복적으로 직접적인 손상을 입음으로써 발생합니다. 손상을 입은 신경은 통증을 동반하는 자극이 없는 경우에도 중추신경계(CNS)에 통증 신호를 보내기 때문에 "자극이 없는 통증' 또는 '환상의 각막'이라고 불립니다. 이러한 상태는 전신성 신경병증성 통증, 복합성 국소 통증 증후군 또는 반사성 교감신경성 이영양증(RSD)의 안과적 형태에 해당합니다. 안과성 또는 각막성 신경병증성 통증, 각막 신경병증, 각막 신경통, 케르타뉴라지아, 그리고 각막 알로디니아는 모두 동일한 질환을 지칭하는 용어입니다.
시장 역학
합리적인 가격의 안과 의료 서비스에 대한 접근성을 개선하기 위한 정부 및 비정부 기구의 노력 증가와 안과 질환에 대한 대중의 인식 제고가 시장 성장을 촉진할 것으로 예상됩니다. 또한 주요 시장 참여자들의 신제품 출시 증가도 예측 기간 중 시장 성장을 지원할 것으로 예상됩니다. 예를 들어 2021년 11월, 캐나다에 본사를 둔 비상장 안과 치료 전문 기업인 I-MED Pharma는 미국에서 안구건조증 치료 제품 전체 라인업을 출시했다고 발표했습니다. "I-DROP"이나 "I-DEFENCE' 등의 제품은 신경병성 안구 통증으로 인한 안구건조증 증상을 장기간 완화하는 것을 목적으로 하고 있습니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 다음의 매개변수를 바탕으로 전 세계 신경병성 안구 통증 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략입니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 신경병성 안구 통증 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 신경병성 안구 통증 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 신경병성 안구 통증 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 신경병성 안구 통증 시장 : 유통 채널별, 2021-2033년
제6장 세계의 신경병성 안구 통증 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.07.09Neuropathic Ocular Pain Market is estimated to be valued at USD 216.6 Mn in 2026 and is expected to reach USD 272.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 216.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.30% | 2033 Value Projection: | USD 272.4 Mn |
Neuropathic pain is a pain condition that's usually chronic. It's usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. This damaged nerve sends pain signals to central nervous system (CNS) even in the absence of painful stimulus, thus, called "pain without stain" or "phantom cornea'. This condition is the ocular analog of systemic neuropathic pain, a complex regional pain syndrome, or reflex sympathetic dystrophy (RSD). Ocular or corneal neuropathic pain, corneal neuropathy, corneal neuralgia, kertaoneuralgia, and corneal allodynia are all terms that are used to describe the same disease entity.
Market Dynamics
An increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth. Moreover, an increase in product launches by key market players is expected to drive the market growth over the forecast period. For instance, in November 2021, I-MED Pharma inc., a privately held Canada based eye care company, announced that it had launched an entire portfolio of dry eye products in the U.S. The products such as I-DROP, I-DEFENCE, and others, are intended to provide long-lasting relief from eye dryness, which is caused due to neuropathic ocular pain.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neuropathic ocular pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include OKYO Pharma, Limited, Ocular Therapeutix, Inc., IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, SALVAT, AbbVie Inc., Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care, Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals and BRIM Biotechnology, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neuropathic ocular pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic ocular pain market
Detailed Segmentation:
- Global Neuropathic Ocular Pain Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Steroids
- Non-Steroidal Anti-Inflammatory Drugs
- Antidepressants
- Anticonvulsants
- Opioids
- Others (Vitamin B supplements, Botulinum toxin A, and others)
- Global Neuropathic Ocular Pain Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Neuropathic Ocular Pain Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- Company Profiles
- OKYO Pharma Limited*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ocular Therapeutix, Inc.
- IACTA Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- SALVAT
- AbbVie Inc.
- Bausch & Lomb Incorporated
- Kala Pharmaceuticals
- Spectra Vision Care.
- Alcon Laboratories
- AERIE PHARMACEUTICALS, INC.
- Optocred Pharmaceuticals
- BRIM Biotechnology, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Pipeline Analysis
4. Global Neuropathic Ocular Pain Market, By Drug Class, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Non-Steroidal Anti-Inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others (Vitamin B supplements, Botulinum toxin A, and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Neuropathic Ocular Pain Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Neuropathic Ocular Pain Market, By Region, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- OKYO Pharma, Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ocular Therapeutix, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- IACTA Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SALVAT
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch & Lomb Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kala Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Spectra Vision Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alcon Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AERIE PHARMACEUTICALS, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Optocred Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BRIM Biotechnology, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
